224 related articles for article (PubMed ID: 2885345)
21. [Use and value of the therapeutic neuroleptic-bromocriptine combination in schizophrenia].
Lombertie ER; Durelle G; Fuseau A
Ann Med Psychol (Paris); 1995 Oct; 153(8):531-4. PubMed ID: 8561400
[TBL] [Abstract][Full Text] [Related]
22. Remoxipride, a selective dopamine D2 receptor antagonist, in tardive dyskinesia.
Andersson U; Häggström JE; Nilsson MI; Widerlöv E
Psychopharmacology (Berl); 1988; 94(2):167-71. PubMed ID: 2895483
[TBL] [Abstract][Full Text] [Related]
23. An open multicentre study of the treatment of florid schizophrenia with remoxipride.
McCreadie RG; Morrison D; Eccleston D; Gall RG; Loudon J; Mitchell MJ
Acta Psychiatr Scand; 1985 Aug; 72(2):139-43. PubMed ID: 2864790
[TBL] [Abstract][Full Text] [Related]
24. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
Chouinard G; Safadi G; Beauclair L
J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
[TBL] [Abstract][Full Text] [Related]
25. An open study of remoxipride, a benzamide derivative, in schizophrenia.
Lindström L; Besev G; Stening G; Widerlöv E
Psychopharmacology (Berl); 1985; 86(1-2):241-3. PubMed ID: 2862658
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of remoxipride controlled release and immediate release capsules in schizophrenic patients.
Widerlöv E; Franzén G; Jansson P; Movin G
Int Clin Psychopharmacol; 1990 Apr; 5(2):125-34. PubMed ID: 1974271
[TBL] [Abstract][Full Text] [Related]
27. Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients.
Faraone SV; Brown WA; Laughren TP
J Clin Psychiatry; 1987 Apr; 48(4):151-4. PubMed ID: 2881923
[TBL] [Abstract][Full Text] [Related]
28. Associations among plasma prolactin levels, tardive dyskinesia, and paranoia in treated schizophrenics: relevance to supersensitivity psychosis.
Csernansky JG; Vinogradov S; Prosser E; Kaplan J; Berger PA; Hollister LE
Psychopharmacol Bull; 1986; 22(3):897-9. PubMed ID: 2879311
[No Abstract] [Full Text] [Related]
29. A placebo controlled trial of remoxipride in the prevention of relapse in chronic schizophrenia.
King DJ; Blomqvist M; Cooper SJ; Doherty MM; Mitchell MJ; Montgomery RC
Psychopharmacology (Berl); 1992; 107(2-3):175-9. PubMed ID: 1352050
[TBL] [Abstract][Full Text] [Related]
30. [Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent].
Ogren SO; Hall H; Köhler C; Magnusson O; Florvall L
Arzneimittelforschung; 1985; 35(8):1227-31. PubMed ID: 2866774
[TBL] [Abstract][Full Text] [Related]
31. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.
Lohr JB; Caligiuri MP
J Clin Psychiatry; 1996 Apr; 57(4):167-73. PubMed ID: 8601552
[TBL] [Abstract][Full Text] [Related]
32. Selective dopamine D2 antagonist and prolactin response in acute schizophrenia--results from remoxipride studies. The Canadian Remoxipride Study Group.
Awad AG; Lapierre YD; Jostell KG
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(5):769-77. PubMed ID: 2149882
[TBL] [Abstract][Full Text] [Related]
33. Antipsychotic effect of remoxipride, a new substituted benzamide with selective antidopaminergic activity.
Lund Laursen A; Gerlach J
Acta Psychiatr Scand; 1986 Jan; 73(1):17-21. PubMed ID: 2938421
[TBL] [Abstract][Full Text] [Related]
34. Mesoridazine and thioridazine: clinical effects and blood levels in refractory schizophrenics.
Vital-Herne J; Gerbino L; Kay SR; Katz IR; Opler LA
J Clin Psychiatry; 1986 Jul; 47(7):375-9. PubMed ID: 2873133
[TBL] [Abstract][Full Text] [Related]
35. A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia.
Laux G; Klieser E; Schröder HG; Dittmann V; Unterweger B; Schubert H; König P; Schöny HW; Bunse J; Beckmann H
Acta Psychiatr Scand Suppl; 1990; 358():125-9. PubMed ID: 1978471
[TBL] [Abstract][Full Text] [Related]
36. Neuroleptic profile of cipazoxapine (Savoxepine), a new tetracyclic dopamine antagonist: clinical validation of the hippocampus versus striatum ratio model of dopamine receptors in animals. A preliminary report.
Butler B; Bech P
Pharmacopsychiatry; 1987 May; 20(3):122-6. PubMed ID: 2885867
[TBL] [Abstract][Full Text] [Related]
37. Clinical and neuroendocrine effects of zotepine--a new neuroleptic drug.
von Bardeleben U; Benkert O; Holsboer F
Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):28-34. PubMed ID: 2883678
[TBL] [Abstract][Full Text] [Related]
38. A double blind comparative multicentre study of remoxipride and haloperidol in schizophrenia.
Andersen J; Kørner A; Ostergaard P; Fensbo C; Birket-Smith M; Thiesen S; Hansen NR; Fogh M; Kristensen M; Møller-Nielsen EM
Acta Psychiatr Scand Suppl; 1990; 358():104-7. PubMed ID: 1978467
[TBL] [Abstract][Full Text] [Related]
39. [Effect of high single doses of bromocriptine in schizophrenic patients with elevated serum prolactin levels and extrapyramidal side effects associated with neuroleptic treatment (author's transl)].
Ringwald E; Lustig A; Moscovici M; Spiegel R; Vamos E
Pharmakopsychiatr Neuropsychopharmakol; 1980 Nov; 13(6):318-24. PubMed ID: 6111093
[TBL] [Abstract][Full Text] [Related]
40. [Difference in prolaction response of schizophrenic patients to equivalent doses of haloperidol, remoxipride and sulpiride].
Liu KL; Lung FW
Kaohsiung J Med Sci; 1996 Dec; 12(12):685-90. PubMed ID: 9011126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
